John A Lawson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7092014/publications.pdf

Version: 2024-02-01

60 papers	2,954 citations	257450 24 h-index	175258 52 g-index
62 all docs	62 docs citations	62 times ranked	3287 citing authors

#	Article	IF	Citations
1	Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet, The, 2016, 388, 2153-2163.	13.7	554
2	GRIN2Bencephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects. Journal of Medical Genetics, 2017, 54, 460-470.	3.2	190
3	Validation of a New Quality of Life Measure for Children with Epilepsy. Epilepsia, 2000, 41, 765-774.	5.1	185
4	TuberOus SClerosis registry to increase disease Awareness (TOSCA) â€“ baseline data on 2093 patients. Orphanet Journal of Rare Diseases, 2017, 12, 2.	2.7	166
5	The Health-Related Quality of Life of Children with Refractory Epilepsy: A Comparison of Those With and Without Intellectual Disability. Epilepsia, 2001, 42, 621-628.	5.1	145
6	Mammalian Target of Rapamycin Inhibitors for Intractable Epilepsy and Subependymal Giant Cell Astrocytomas in Tuberous Sclerosis Complex. Journal of Pediatrics, 2014, 164, 1195-1200.	1.8	139
7	Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex. JAMA Neurology, 2021, 78, 285.	9.0	139
8	TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. Orphanet Journal of Rare Diseases, 2018, 13, 157.	2.7	106
9	Cerebral and Cerebellar Volume Reduction in Children with Intractable Epilepsy. Epilepsia, 2000, 41, 1456-1462.	5.1	96
10	Everolimus for treatment-refractory seizures in TSC. Neurology: Clinical Practice, 2018, 8, 412-420.	1.6	85
11	Integrating exome sequencing into a diagnostic pathway for epileptic encephalopathy: Evidence of clinical utility and cost effectiveness. Molecular Genetics & Genomic Medicine, 2018, 6, 186-199.	1.2	83
12	Management Strategies for CLN2 Disease. Pediatric Neurology, 2017, 69, 102-112.	2.1	80
13	Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial. The Lancet Child and Adolescent Health, 2018, 2, 495-504.	5.6	77
14	Ten-Year Single-Center Experience of the Ketogenic Diet: Factors Influencing Efficacy, Tolerability, and Compliance. Journal of Pediatrics, 2015, 166, 1030-1036.e1.	1.8	66
15	Eye movement disorders are an early manifestation of <scp>CACNA</scp>1A mutations in children. Developmental Medicine and Child Neurology, 2016, 58, 639-644.	2.1	58
16	Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness. Nephrology Dialysis Transplantation, 2019, 34, 502-508.	0.7	55
17	Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience. European Journal of Paediatric Neurology, 2018, 22, 1066-1073.	1.6	54
18	Diagnostic Yield of Whole Genome Sequencing After Nondiagnostic Exome Sequencing or Gene Panel in Developmental and Epileptic Encephalopathies. Neurology, 2021, 96, e1770-e1782.	1.1	53

#	Article	IF	Citations
19	Everolimus dosing recommendations for <scp>tuberous sclerosis complexâ€“</scp>associated refractory seizures. Epilepsia, 2018, 59, 1188-1197.	5.1	41
20	ILAE-Defined Epilepsy Syndromes in Children: Correlation with Quantitative MRI. Epilepsia, 1998, 39, 1345-1349.	5.1	33
21	Outcomes of deviation from treatment guidelines in status epilepticus: A systematic review. Seizure: the Journal of the British Epilepsy Association, 2018, 58, 147-153.	2.0	32
22	Cannabidiol for treating drugâ€resistant epilepsy in children: the New South Wales experience. Medical Journal of Australia, 2018, 209, 217-221.	1.7	28
23	Early Detection of Tuberous Sclerosis Complex: An Opportunity for Improved Neurodevelopmental Outcome. Pediatric Neurology, 2017, 76, 20-26.	2.1	27
24	Renal Manifestations of Tuberous Sclerosis Complex: Key Findings From the Final Analysis of the TOSCA Study Focussing Mainly on Renal Angiomyolipomas. Frontiers in Neurology, 2020, 11, 972.	2.4	27
25	Clinicopathological associations in temporal lobe epilepsy patients utilising the current ILAE focal cortical dysplasia classification. Epilepsy Research, 2014, 108, 1345-1351.	1.6	25
26	Theory of Mind and social competence in children and adolescents with genetic generalised epilepsy (GGE): Relationships to epilepsy severity and anti-epileptic drugs. Seizure: the Journal of the British Epilepsy Association, 2018, 60, 96-104.	2.0	23
27	Measuring Health-Related Quality of Life in Tuberous Sclerosis Complex â€“ Psychometric Evaluation of Three Instruments in Individuals With Refractory Epilepsy. Frontiers in Pharmacology, 2018, 9, 964.	3.5	22
28	Clinical Characteristics of Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex. Frontiers in Neurology, 2019, 10, 705.	2.4	22
29	Quantitative MRI in Outpatient Childhood Epilepsy. Epilepsia, 1997, 38, 1289-1293.	5.1	20
30	Frequency and predictors of psychological distress after a diagnosis of epilepsy: A community-based study. Epilepsy and Behavior, 2017, 75, 190-195.	1.7	20
31	Burden of Illness and Quality of Life in Tuberous Sclerosis Complex: Findings From the TOSCA Study. Frontiers in Neurology, 2020, 11, 904.	2.4	20
32	Tuberous Sclerosis Complex Associated with Vascular Anomalies or Overgrowth. Pediatric Dermatology, 2016, 33, 536-542.	0.9	18
33	Newly Diagnosed and Growing Subependymal Giant Cell Astrocytoma in Adults With Tuberous Sclerosis Complex: Results From the International TOSCA Study. Frontiers in Neurology, 2019, 10, 821.	2.4	18
34	Clustered mutations in the GRIK2 kainate receptor subunit gene underlie diverse neurodevelopmental disorders. American Journal of Human Genetics, 2021, 108, 1692-1709.	6.2	18
35	The Severity of Gliosis in Hippocampal Sclerosis Correlates with Pre-Operative Seizure Burden and Outcome After Temporal Lobectomy. Molecular Neurobiology, 2016, 53, 5446-5456.	4.0	17
36	The natural history of subependymal giant cell astrocytomas in tuberous sclerosis complex: a review. Reviews in the Neurosciences, 2018, 29, 295-301.	2.9	17

#	Article	IF	Citations
37	Natural clusters of tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND): new findings from the TOSCA TAND research project. Journal of Neurodevelopmental Disorders, 2020, 12, 24.	3.1	16
38	Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia. Haematologica, 2022, 107, 635-643.	3.5	16
39	Adjunctive everolimus therapy for tuberous sclerosis complexâ€associated refractory seizures: Results from the postextension phase of EXISTâ€3. Epilepsia, 2021, 62, 3029-3041.	5.1	16
40	Rare manifestations and malignancies in tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increAse disease awareness (TOSCA). Orphanet Journal of Rare Diseases, 2021, 16, 301.	2.7	15
41	Historical Patterns of Diagnosis, Treatments, and Outcome of Epilepsy Associated With Tuberous Sclerosis Complex: Results From TOSCA Registry. Frontiers in Neurology, 2021, 12, 697467.	2.4	13
42	Treatment Patterns and Use of Resources in Patients With Tuberous Sclerosis Complex: Insights From the TOSCA Registry. Frontiers in Neurology, 2019, 10, 1144.	2.4	11
43	Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. Epilepsia, 2022, 63, 1736-1747.	5.1	11
44	Facial emotion perception and social competence in children (8 to 16â€¯years old) with genetic generalized epilepsy and temporal lobe epilepsy. Epilepsy and Behavior, 2019, 100, 106301.	1.7	10
45	TuberOus SClerosis registry to increAse disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex. Frontiers in Neurology, 2021, 12, 630378.	2.4	10
46	Exploring carer perceptions of training in out-of-hospital use of buccal midazolam for emergency management of seizures (2008-2012). Journal of Paediatrics and Child Health, 2015, 51, 704-707.	0.8	8
47	Therapeutic use of medicinal cannabis in difficult to manage epilepsy. British Journal of Clinical Pharmacology, 2018, 84, 2488-2490.	2.4	8
48	Accelerated long-term forgetting in children with genetic generalized epilepsy: The temporal trajectory and contribution of executive skills. Epilepsy and Behavior, 2020, 113, 107471.	1.7	8
49	Expert advice for prescribing cannabis medicines for patients with epilepsyâ€”drawn from the Australian clinical experience. British Journal of Clinical Pharmacology, 2022, 88, 3101-3113.	2.4	8
50	Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders (TAND): New Findings on Age, Sex, and Genotype in Relation to Intellectual Phenotype. Frontiers in Neurology, 2020, 11, 603.	2.4	7
51	Managing tuberous sclerosis in the Asia-Pacific region: Refining practice and the role of targeted therapy. Journal of Clinical Neuroscience, 2014, 21, 1180-1187.	1.5	6
52	Cannabis for paediatric epilepsy: challenges and conundrums. Medical Journal of Australia, 2018, 208, 132-136.	1.7	6
53	Anti-N-methyl-D-aspartate encephalitis â€“ a case study of symptomatic progression. Australasian Psychiatry, 2015, 23, 422-425.	0.7	5
54	Management of status epilepticus in children prior to medical retrieval: Deviations from the guidelines. Journal of Paediatrics and Child Health, 2019, 55, 1458-1462.	0.8	5

#	Article	IF	Citations
55	Congenital subpendymal giant cell astrocytoma in children with tuberous sclerosis complex: growth patterns and neurological outcome. Pediatric Research, 2021, 89, 1447-1451.	2.3	5
56	Accelerated long-term forgetting in children with temporal lobe epilepsy: A timescale investigation of material specificity and executive skills. Epilepsy and Behavior, 2022, 129, 108623.	1.7	4
57	The TOSCA Registry for Tuberous Sclerosisâ€"Lessons Learnt for Future Registry Development in Rare and Complex Diseases. Frontiers in Neurology, 2019, 10, 1182.	2.4	3
58	The need for improved management of status epilepticus in children in Australia: Time from seizure onset to treatment is consistently delayed. Journal of Paediatrics and Child Health, 2021, , .	0.8	3
59	Successful epilepsy surgery for tuberous sclerosis complex evaluated by stereoelectroencephalography. Epileptic Disorders, 2020, 22, 633-641.	1.3	1
60	Response to â€œAbout Focal Cortical Dysplasia (FCD) type IIIaâ€• Epilepsy Research, 2014, 108, 1958-1959.	1.6	0